Molecular Imaging in Drug R and D and Medical Practice Technologies, Applications, Markets
Chapter 1
INTRODUCTION
1.1. Biomarker Definitions
1.2. Organization of the Report
Chapter 2
IN VIVO MOLECULAR IMAGING TECHNOLOGIES
2.1. Historical Introduction
2.2. Imaging Technologies
Computed Tomography
Positron Emission Tomography
Single Photon Emission Computed Tomography
Magnetic Resonance Imaging
Ultrasound
Optical Imaging
2.3. Combination Technologies
2.4. Molecular and Functional Imaging
Chapter 3
IMAGING BIOMARKERS IN DRUG DEVELOPMENT
3.1. Preclinical Development
3.2. Clinical Development
3.3. Therapeutic Areas
Cancer
Cell Proliferation or Metabolism
Apoptosis
Angiogenesis
Hypoxia
Other Parameters
Neurological Disease
Alzheimer's Disease
Parkinson's Disease
Cardiovascular Disease
Inflammatory and Autoimmune Disease
Chapter 4
MOLECULAR IMAGING IN DIAGNOSTICS
4.1. Cancer
4.2. Cardiovascular Disease
4.3. Neurological Disease
Chapter 5
CONSORTIA, GOVERNMENT, AND REGULATORY CONSIDERATIONS
5.1. Consortia and Professional Society Involvement
Biomarkers Consortium
Oncology Biomarker Qualification Initiative (OBQI)
Uniform Protocols for Imaging in Clinical Trials (UPICT)
Imaging Response Assessment Teams (IRATs)
5.2. Government Involvement
NIH Molecular Libraries and Imaging Roadmap
Network for Translational Research: Optical Imaging (NTROI)
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Institute for Molecular Technology (IMT)
National Oncologic PET Registry (NOPR)
5.3. FDA Regulatory Guidance
5.4. National Academy of Sciences Report
Chapter 6
MARKET CONSIDERATIONS
6.1. The Molecular Imaging Market Ecology
Radiopharmaceuticals
Instruments
Software
6.2. Market Analysis and Dynamics
Facilitation of Imaging Agent Development
PET Versus SPECT
6.3. Drug Discovery and Development Market
Large Company Business Models
The Convergence of In Vitro and In Vivo Diagnostics
6.4. Deals in Molecular Imaging
Categorization of Deals
Market Size and Growth Projects
Chapter 7
EXPERT INTERVIEWS
Sudeep Chandra, PhD, General Manager of Molecular Imaging, Philips Healthcare
Terry A. Colip, Managing Partner and CFO, Cell>Point, LLC
J. James Frost, MD, PhD, Professor of Radiology and Psychiatry, Yale University,
School of Medicine
Antony Gee, PhD, Director of PET and Radiotracer Development, GlaxoSmithKline
Franz Hefti, PhD, Chief Scientific Officer, Avid Radiopharmaceuticals
Patrick McConville, PhD, Director of Imaging, MIR Preclinical Services
Jean-Luc Vanderheyden, PhD, Global Molecular Imaging Leader, GE Healthcare
APPENDIX
INSIGHT PHARMA REPORTS MOLECULAR IMAGING SURVEY-OCTOBER 2007
Observations from the Survey
References
Company Index with Web Addresses
Tables
Table 2.1. Imaging Technology Timeline
Table 4.1. PET Scan Procedures Eligible for Reimbursement to Medicare Recipients
Table 6.1. Selected Recent Deals in Molecular Imaging
Table 6.2. Worldwide Molecular Imaging Instrument Revenues, 2007 Estimates and 2012 Projections
Table 6.3. Worldwide Molecular Imaging Reagent Revenues, 2007 Estimates and 2012 Projections
Figures
Figure 2.1. Chest X-ray Image
Figure 2.2. CT Image of the Abdomen
Figure 2.3. CT Fan Beam and Configuration
Figure 2.4. Schematic of the PET Scanning Process
Figure 3.1. Control Versus Velcade Treatment of a Mouse Carrying Human Prostate Cancer Xenograft
Figure 3.2. Optical Imaging of a Mouse Injected with a Probe Targeted to Brain Amyloid Plaque
Figure 3.3. Mouse Vasculature Envisioned by High-Resolution Micro-CT
Figure 3.4. FDG-PET Tumor Scans Taken Before Treatment and 7 Days After the Start of Treatment
Appendix Figures
Figure 1A. Response by Sector
Figure 2A. Response by Title
Figure 3A. Stage of Respondents’ Work
Figure 4A. Respondents’ Area of Work
Figure 5A. Technologies Used by Respondents’ Organizations
Figure 6A. Involvement in Molecular Imaging for Preclinical Development
Figure 7A. Means by Which Preclinical Molecular Imaging Studies Are Conducted
Figure 8A. Technologies Used in In Vivo Molecular Imaging for Preclinical Development
Figure 9A. Involvement in Molecular Imaging for Clinical Development
Figure 10A. Approaches Used for Molecular Imaging in Clinical Studies
Figure 11A. Standardization of Instruments and Methods
Figure 12A. Molecular Imaging in Oncology Applications
Figure 13A. Molecular Imaging in Neurological Applications
Figure 14A. Involvement with Disease Areas Other than Oncological and Neurological
Figure 15A. Outlook for Fiscal 2008 Molecular Imaging Expenditures
Figure 16A. Outlook for Molecular Imaging Expenditures During the Next 3 Years